Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
4 of 4 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Omega-3 and Oxiracetam have evidence — compare verdict strength side-by-side.
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
800-2400mg daily in divided doses
Morning and early afternoon, Divided into 2-3 doses, With choline source
Oxiracetam powder or capsules
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
1-2 weeks
1-2 weeks
1-2 weeks
If choline-deficient
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment
Pakistan journal of pharmaceutical sciences (2020) · Rct · n=120
The combined group had the highest effective rate and the total effective rate was 93.3%.
A Meta-Analysis of Au/Polypropionic Acid Nanoparticles Loaded with Olacetam for the Treatment of Vascular Cognitive Impairment
Journal of nanoscience and nanotechnology (2020) · Meta analysis
The results of the meta-analysis showed that compared with placebo and other medications, oxiracetam significantly improved the mental status of patients, Concise Mental State Checklist score [mean difference (MD)= 5.29, P < 0.01] and Montreal Cognitive Assessment score (MD = 4.32, P < 0.01).
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
Based on multiple meta-analyses showing cognitive improvements in vascular dementia and stroke populations. One major RCT (n=500) showed no benefit for post-stroke cognitive impairment, limiting confidence. Effects may be population-specific and less pronounced in healthy individuals.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 5/10) and wins in 2 of 3 categories.
For sharpen focus, Oxiracetam has a higher relevance score (75 vs 70).
No known interactions between Omega-3 and Oxiracetam have been documented in our database. However, always consult a healthcare provider before combining supplements.